MUKFourteen
Research type
Research Study
Full title
A Phase I/II trial investigating the combination of Pembrolizumab (Keytruda) with Cyclophosphamide and Lenalidomide (Revlimid) for patients with relapsed multiple myeloma
IRAS ID
220512
Contact name
Rakesh Popat
Contact email
Sponsor organisation
University of Leeds
Eudract number
2016-003955-31
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Multiple myeloma is an incurable haematological malignancy with approx 4700 people diagnosed in the UK each year.
Lenalidomide and dexamethasone is approved for use in the NHS by NICE and shows good response rates in patients with relapsed disease. Cyclophosphamide is usually combined with lenalidomide and dexamethasone to enhance efficacy.
Pembrolizumab is a monocolonal antibody that blocks PD1 and inhibits cell reactions. It has been shown to be effective in melanoma (a type of skin cancer) and is now being tested in myeloma in this trial.
The purpose of this trial is to assess safety and efficacy of pembrolizumab in combination with cyclophosphamide and lenalidomide for patients with relapsed multiple myeloma. This combination is hoped to optimise the anti myeloma response and remain tolerable to patients.REC name
London - Harrow Research Ethics Committee
REC reference
17/LO/0795
Date of REC Opinion
12 Jul 2017
REC opinion
Further Information Favourable Opinion